Could a diabetes drug slow MS brain damage?
NCT ID NCT07497399
First seen Apr 01, 2026
Summary
This phase 2 trial tests whether NLY01, a drug similar to those used for diabetes, can slow brain and retinal shrinkage in people with multiple sclerosis. About 120 adults with stable MS will receive either NLY01 or a placebo for 96 weeks. The main goal is to see if the drug reduces brain tissue loss measured by MRI.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NLY01 (a modified version of the diabetes drug exenatide)
What this could lead to
If it works, this could point toward a new way to slow nerve damage and preserve brain tissue in people with multiple sclerosis.
What could go wrong
This is a mid-stage trial with only 120 participants, so results may not apply to everyone. The drug also carries risks like nausea, pancreatitis, and thyroid tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.